Comparative effectiveness of cryotherapy vs brachytherapy for localised prostate cancer

BJU International

Volumn 110, Issue , 2012, Pages

  Williams, Stephen B ^a   Lei, Yin ^a   Nguyen, Paul L ^a   Gu, Xiangmei ^b   Lipsitz, Stuart R ^b   Yu, Hua Yin ^a   Kowalczyk, Keith J ^a   Hu, Jim C ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Center for Surgery   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

and End Results (SEER); brachytherapy; complications; cryotherapy; Epidemiology; prostate cancer; Surveillance

Indexed keywords

AGE; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CRYOTHERAPY; CYSTITIS; EDUCATIONAL STATUS; ERECTILE DYSFUNCTION; FOLLOW UP; HEALTH CARE COST; HUMAN; INCOME; INTERMETHOD COMPARISON; INTESTINAL BLEEDING; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; RECTUM INJURY; RECTUM ULCER; URBAN RURAL DIFFERENCE; URETHRA FISTULA; URETHRA STRICTURE; URINE RETENTION;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CRYOTHERAPY; ERECTILE DYSFUNCTION; HUMANS; MALE; PROPENSITY SCORE; PROSTATIC NEOPLASMS; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 84863543298     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10775.x     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49
2. Han KR, Cohen JK, Miller RJ, et al,. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol 2003; 170: 1126-30
3. Katz AE, Rewcastle JC,. The current and potential role of cryoablation as a primary therapy for localized prostate cancer. Curr Oncol Rep 2003; 5: 231-8
4. Mouraviev V, Polascik TJ,. Update on cryotherapy for prostate cancer in 2006. Curr Opin Urol 2006; 16: 152-6
5. Rees J, Patel B, MacDonagh R, Persad R,. Cryosurgery for prostate cancer. BJU Int 2004; 93: 710-4
6. Donnelly BJ, Saliken JC, Ernst DS, et al,. Prospective trial of cryosurgical ablation of the prostate: five-year results. Urology 2002; 60: 645-9
7. Polascik TJ, Nosnik I, Mayes JM, Mouraviev V,. Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology. Urology 2007; 70: 117-21
8. Prepelica KL, Okeke Z, Murphy A, Katz AE,. Cryosurgical ablation of the prostate: high risk patient outcomes. Cancer 2005; 103: 1625-30
9. Babaian RJ, Donnelly B, Bahn D, et al,. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol 2008; 180: 1993-2004
10. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR,. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007; 178: S14-9
11. Malcolm JB, Fabrizio MD, Barone BB, et al,. Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer. J Urol 2010; 183: 1822-8
12. Heidenreich A, Aus G, Bolla M, et al,. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80
13. Chen AB, D'Amico AV, Neville BA, Earle CC,. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol 2006; 24: 5298-304
14. Aus G, Pileblad E, Hugosson J,. Cryosurgical ablation of the prostate: 5-year follow-up of a prospective study. Eur Urol 2002; 42: 133-8
15. De La Taille A, Benson MC, Bagiella E, et al,. Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence. BJU Int 2000; 85: 281-6
16. Klabunde CN, Potosky AL, Legler JM, Warren JL,. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000; 53: 1258-67
17. Hu JC, Wang Q, Pashos CL, Lipsitz SR, Keating NL,. Utilization and outcomes of minimally invasive radical prostatectomy. J Clin Oncol 2008; 26: 2278-84
18. Hu JC, Hevelone ND, Ferreira MD, et al,. Patterns of care for radical prostatectomy in the United States from 2003 to 2005. J Urol 2008; 180: 1969-74
19. Hu JC, Gu X, Lipsitz SR, et al,. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 2009; 302: 1557-64
20. Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg JE,. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst 1996; 88: 166-73
21. Paulson HM, Chao EL, Leavitt MO, et al,. Annual Report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Fund. 2008. Available at:. Accessed October 2011.
22. Rubin DB,. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127: 757-63
23. Robins JM, Hernan MA, Brumback B,. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11: 550-60
24. Damber JE, Aus G,. Prostate cancer. Lancet 2008; 371: 1710-21
25. Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M,. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 2002; 60 (Suppl. 1): 3-11
26. Ambs A, Warren JL, Bellizzi KM, Topor M, Haffer SC, Clauser SB,. Overview of the SEER-Medicare Health Outcomes Survey linked dataset. Health Care Financ Rev 2008; 29: 5-21
27. Lawthers AG, McCarthy EP, Davis RB, Peterson LE, Palmer RH, Iezzoni LI,. Identification of in-hospital complications from claims data. Is it valid? Med Care 2000; 38: 785-95
28. Hubosky SG, Fabrizio MD, Schellhammer PF, Barone BB, Tepera CM, Given RW,. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life. J Endourol 2007; 21: 1521-31
29. Robinson JW, Donnelly BJ, Saliken JC, Weber BA, Ernst S, Rewcastle JC,. Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery. Urology 2002; 60 (Suppl. 1): 12-8
30. Phan J, Swanson DA, Levy LB, Kudchadker RJ, Bruno TL, Frank SJ,. Late rectal complications after prostate brachytherapy for localized prostate cancer: incidence and management. Cancer 2009; 115: 1827-39
31. Kollmeier MA, Stock RG, Stone N,. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 2003; 57: 645-53
32. Saliken JC, Donnelly BJ, Rewcastle JC,. The evolution and state of modern technology for prostate cryosurgery. Urology 2002; 60 (Suppl. 1): 26-33
33. Stone NN, Stock RG, White I, Unger P,. Patterns of local failure following prostate brachytherapy. J Urol 2007; 177: 1759-64
34. Cohen JK, Miller RJ Jr, Ahmed S, Lotz MJ, Baust J,. Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology 2008; 71: 515-8
35. Hummel S, Paisley S, Morgan A, Currie E, Brewer N,. Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review. Health Technol Assess 2003; 7: iii, ix-x, 1-157
36. Stanford JL, Feng Z, Hamilton AS, et al,. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000; 283: 354-60